% | $
Quotes you view appear here for quick access.

Abbott Laboratories Message Board

  • kralcekim kralcekim Apr 22, 2008 3:49 PM Flag

    Is Xience's approval priced in?

    I ask because I'm looking at making an entry in ABT. The dividend is nice, it's nice this price 4 times in the past couple years and bounced back everytime.

    My only concern/question is the approval of Xience priced in? With the stock price depreciated I would assume not, also with all the issues in the stent industry I would assume not but...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The approval of Xience is fully priced into today's closing ABT price.

      Before investing in this stock please read post titled Seeking alph Slams ABT by Web, the post with 4 star reccomendations.

      ABT is waste of time and money.

      • 1 Reply to jak.stat
      • Here's the latest:

        Patients using Abbott's device, the Xience drug-eluting stent, had far fewer heart attacks and heart-related deaths after one year, the researchers reported in the Journal of the American Medical Association.

        The device has already won the backing of a U.S. advisory panel to the Food and Drug Administration and is expected to win U.S. marketing approval in June, joining Medtronic Inc's (MDT.N: Quote, Profile, Research) new drug-eluting stent, Endeavor, which won U.S. approval in February.

        It's really an unknown whether it is priced in or not. But, the fact is that ABT is producing good top and bottom line increases. I still think that if ABT can continue its recent trend, its price will most certainly move higher, possibly over 60 within the next 12 months.

    • I don't think so. Once approved, I believe ABT's price will go higher. However, if it is not approved, its price may go even lower. Having said that, FDA does not any reason not to's just a matter of time.

      If ABT could continue to produce double digit sales and earnings growth, its price has no choice but to follow suit and move higher.

42.29-0.04(-0.09%)2:44 PMEDT